Durvalumab Plus FLOT Ups Survival in Early Upper-GI Cancer – Medscape

  1. Durvalumab Plus FLOT Ups Survival in Early Upper-GI Cancer  Medscape
  2. AstraZeneca – IMFINZI-Based Regimen Reduced The Risk Of Death By 22% In Early Gastric Cancer Versus. Chemotherapy Alone In MATTERHORN Phase III Trial  TradingView
  3. MATTERHORN Trial at ESMO 2025: Durvalumab Plus FLOT in Resectable Gastric and GEJ Adenocarcinoma  Oncodaily
  4. Imfinzi Plus Chemo Improves Survival in G/GEJ Adenocarcinoma  CUREtoday.com
  5. Durvalumab Plus Chemotherapy Sets New Standard in Resectable Gastric and GEJ Cancer  Pharmacy Times

Continue Reading